Investigation of the Efficacy and Safety of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma
Investigation of the Efficacy and Safety of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma
复制标题
DOI：
10.21873/invivo.12127
复制
发表时间：
2020-09-01
期刊：
影响因子：
2.3
通讯作者：
Tsukahara, Kiyoaki
中科院分区：
文献类型：
--
作者：
Sato, Hiroki;Fushimi, Chihiro;Tsukahara, Kiyoaki
背景/目的：Nivolumab是一种抗PD-1抑制剂，已在几种类型的复发性和转移性（R/M）头颈部鳞状细胞癌患者中证明了疗效。我们评估了接受纳武单抗的R/M-NPC患者。患者和方法：12例R/M-NPC患者在4个机构入组。主要终点是总生存期，次要终点是i）无进展生存期（PFS），ii）总缓解率（ORR），iii）疾病控制率（DCR）和iv）治疗相关毒性。结果：1年生存率为75.8%，中位PFS为2.8个月，1年PFS率为33.3%。最佳治疗反应为2例完全缓解，3例病情稳定，7例病情进展。所有患者的ORR为16.7%，DCR为41.7%。结论：纳武利尤单抗是R/M-NPC患者有用且相对安全的二线全身治疗，即使对纳武利尤单抗无反应的患者也可能存活较长时间。
Background/Aim: Nivolumab, an anti-PD-1 inhibitor, has demonstrated efficacy in patients with several types of recurrent and metastatic (R/M) squamous cell carcinoma of the head and neck. We evaluated patients with R/M-NPC receiving nivolumab. Patients and Methods: Twelve patients with R/M-NPC were enrolled at 4 institutions. The primary endpoint was overall survival, and secondary endpoints were i) progression free survival (PFS), ii) overall response rate (ORR), iii) disease control rate (DCR), and iv) treatment-related toxicity. Results: The 1-year survival rate was 75.8%, the median PFS was 2.8 months, and the 1-year PFS rate was 33.3%. The best therapeutic response was complete response in 2, stable disease in 3 and progressive disease in 7 patients. The ORR of all patients was 16.7% and the DCR was 41.7%. Conclusion: Nivolumab is a useful and relatively safe second-line systemic therapy in patients with R/M-NPC, and even patients who do not respond to nivolumab may survive for a long time.